Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer/Experiment 2
From BugSigDB
Subjects
- Location of subjects
- Taiwan
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Breast carcinoma breast cancer,breast cancer, NOS,breast carcinoma,cancer of breast,cancer of the breast,cancer, breast,carcinoma of breast,carcinoma of the breast,mammary carcinoma,Breast carcinoma
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- postmenopausal female controls (Post-C)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- postmenopausal breast cancer patients (Post-BC)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with postmenopausal breast cancer
- Group 0 sample size Number of subjects in the control (unexposed) group
- 17
- Group 1 sample size Number of subjects in the case (exposed) group
- 100
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- Within 4 weeks
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2.0
Signature 1
Source: FIG 2 (C)
Description: Microbial markers at the genus/species levels between control individuals and breast cancer patients. The potential microbial markers between Post-C and Post-BC.
Abundance in Group 1: increased abundance in postmenopausal breast cancer patients (Post-BC)
| NCBI | Quality Control | Links |
|---|---|---|
| Actinomyces | ||
| Mitsuokella | ||
| Haemophilus | ||
| Sutterella | ||
| Mitsuokella multacida | ||
| Haemophilus parainfluenzae |
Revision editor(s): Rahila
Signature 2
Source: FIG 2 (C)
Description: Microbial markers at the genus/species levels between control individuals and breast cancer patients. The potential microbial markers between Post-C and Post-BC.
Abundance in Group 1: decreased abundance in postmenopausal breast cancer patients (Post-BC)
Revision editor(s): Rahila
